Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E.

Circulation. 2015 Sep 29;132(13):1224-33. doi: 10.1161/CIRCULATIONAHA.115.018381. Epub 2015 Sep 1.

PMID:
26330412
2.

Dyslipidemia and cardiovascular disease in women.

Cífková R, Krajčoviechová A.

Curr Cardiol Rep. 2015 Jul;17(7):609. doi: 10.1007/s11886-015-0609-5. Review.

PMID:
26026998
3.

Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.

Cao X, Ejzykowicz F, Ramey DR, Sajjan S, Ambegaonkar BM, Mavros P, Tunceli K.

Clin Ther. 2015 Apr 1;37(4):804-15. doi: 10.1016/j.clinthera.2014.12.019. Epub 2015 Jan 24.

PMID:
25626487
4.

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.

Ballantyne CM, Hoogeveen RC, Raya JL, Cain VA, Palmer MK, Karlson BW; GRAVITY Study Investigators.

Atherosclerosis. 2014 Jan;232(1):86-93. doi: 10.1016/j.atherosclerosis.2013.10.022. Epub 2013 Nov 1.

PMID:
24401221
5.

The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders.

Yang CW, Mousa SA.

Complement Ther Med. 2012 Dec;20(6):466-74. doi: 10.1016/j.ctim.2012.07.004. Epub 2012 Aug 17. Review.

PMID:
23131380
6.

Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.

Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, De Tilleghem Cle B, Milardo C, Triscari J.

Lipids Health Dis. 2012 Jan 31;11:18. doi: 10.1186/1476-511X-11-18.

7.

Pitavastatin: clinical effects from the LIVES Study.

Teramoto T.

Atheroscler Suppl. 2011 Nov;12(3):285-8. doi: 10.1016/S1567-5688(11)70888-1. Review.

PMID:
22152283
8.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
9.

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE.

JAMA. 2011 Nov 16;306(19):2099-109. doi: 10.1001/jama.2011.1649.

PMID:
22089718
10.

Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial.

Eriksson M, Budinski D, Hounslow N.

Adv Ther. 2011 Sep;28(9):811-23. doi: 10.1007/s12325-011-0056-7. Epub 2011 Aug 25.

PMID:
21874538
11.

Long-term efficacy of pitavastatin versus simvastatin.

Eriksson M, Budinski D, Hounslow N.

Adv Ther. 2011 Sep;28(9):799-810. doi: 10.1007/s12325-011-0057-6. Epub 2011 Aug 25.

PMID:
21874537
12.

Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.

Yoon HS, Kim SH, Kim JK, Ko SH, Ko JE, Park SJ, Park MG, Lee JH, Hyon MS.

Ann Pharmacother. 2011 Jul;45(7-8):841-9. doi: 10.1345/aph.1P511. Epub 2011 Jun 21. Erratum in: Ann Pharmacother. 2011 Sep;45(9):1172.

PMID:
21693699
16.

Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.

Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D.

Int Angiol. 2010 Dec;29(6):514-24.

PMID:
21173733
17.

Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.

Ramachandran S, Saraf S, Shetty C, Capps N, Bailey C.

Ann Clin Biochem. 2011 Jan;48(Pt 1):75-8. doi: 10.1258/acb.2010.010081. Epub 2010 Nov 29.

PMID:
21115572
18.

Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.

McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P; IN-PRACTICE study.

Int J Clin Pract. 2010 Jul;64(8):1052-61. doi: 10.1111/j.1742-1241.2010.02429.x. Epub 2010 May 12.

PMID:
20487050
19.

Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.

Lakoski SG, Xu F, Vega GL, Grundy SM, Chandalia M, Lam C, Lowe RS, Stepanavage ME, Musliner TA, Cohen JC, Hobbs HH.

J Clin Endocrinol Metab. 2010 Feb;95(2):800-9. doi: 10.1210/jc.2009-1952. Epub 2009 Dec 4. Erratum in: J Clin Endocrinol Metab. 2011 May;96(5):1582.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk